These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10332707)

  • 1. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
    Albright ES; Desmond R; Bell DS
    Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of lispro for high sugar content snacks between meals in intensive insulin regimens.
    Kong N; Kitchen MM; Ryder RE
    Diabet Med; 2000 Apr; 17(4):331-2. PubMed ID: 10821304
    [No Abstract]   [Full Text] [Related]  

  • 6. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen.
    Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB
    Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953
    [No Abstract]   [Full Text] [Related]  

  • 7. Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes.
    Zinman B
    Endocr Pract; 2000; 6(1):88-92. PubMed ID: 11419927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
    Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
    Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.
    Heise T; Weyer C; Serwas A; Heinrichs S; Osinga J; Roach P; Woodworth J; Gudat U; Heinemann L
    Diabetes Care; 1998 May; 21(5):800-3. PubMed ID: 9589244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmaceutical development and clinical experiment of new antidiabetic drugs, premixed preparations of insulin lispro (Humalog Mix 25 and Humalog Mix 50) and intermediate-acting insulin lispro (Humalog N)].
    Awa T; Nakata T; Shigeta H
    Nihon Yakurigaku Zasshi; 2005 Aug; 126(2):143-51. PubMed ID: 16205018
    [No Abstract]   [Full Text] [Related]  

  • 13. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

  • 14. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
    Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
    Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients.
    Masuda H; Sakamoto M; Irie J; Kitaoka A; Shiono K; Inoue G; Atsuda K; Yamada S
    Diabetes Obes Metab; 2008 Dec; 10(12):1261-5. PubMed ID: 18494811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin lispro (Humalog), a novel fast-acting insulin analogue: guidelines for its practical use.
    Nobels FR; Hermans MP; De Leeuw I
    Acta Clin Belg; 1999 Oct; 54(5):246-54. PubMed ID: 10555382
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of mixing glargine and short-acting insulin analogs on glucose control.
    Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
    Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG; Zeise TM; Burge MR; Schade DS
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspects of Insulin Lispro (LY275585)].
    Kuzuya T
    Nihon Rinsho; 1997 Nov; 55 Suppl():298-305. PubMed ID: 9434484
    [No Abstract]   [Full Text] [Related]  

  • 20. Updating the insulin lispro file.
    Grossman LD
    CMAJ; 1998 May; 158(9):1132-3. PubMed ID: 9597962
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.